EyePoint
Develops sustained-release retinal therapies built around DURAVYU and Durasert E technology.
Something off on this page? Send us feedback.
Profile
Develops sustained-release retinal therapies for wet AMD and diabetic macular edema, with DURAVYU as the central late-stage program. Operations are U.S.-based and centered on Durasert E drug delivery, a Massachusetts manufacturing base, and legacy YUTIQ economics rather than a broad commercial product portfolio.
Develops ophthalmic products for serious retinal diseases, led by DURAVYU, an investigational sustained-release vorolanib insert built on Durasert E. Current work centers on wet AMD and diabetic macular edema, with EYP-2301 adding an earlier retinal-disease program using the same delivery platform.
Operations are concentrated in the United States, with headquarters and research in Watertown, Massachusetts, and a Northbridge facility built to support DURAVYU manufacturing if approved. The business reports one segment, so pipeline programs and legacy economics define the operating picture more than formal segment lines.
Execution depends on pivotal trial results, regulatory review, manufacturing readiness, and launch preparation for DURAVYU. YUTIQ is no longer the main commercial asset, but prior rights sales and royalty arrangements remain economically relevant.
Company facts
Key statistics
Year to date −74.4% · Average volume (30d) 5.0M
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Prior target | Target |
|---|---|---|---|---|---|---|
| Aug 18, 2026 | Chardan Capital | Downgrade | Buy | Neutral | $5 | |
| Aug 18, 2026 | H.C. Wainwright | Downgrade | Buy | Neutral | ||
| Aug 18, 2026 | HC Wainwright & Co. | Downgrade | Buy | Neutral | ||
| Aug 18, 2026 | RBC Capital | Downgrade | Outperform | Sector Perform | ||
| Aug 17, 2026 | RBC Capital | Downgrade | Outperform | Sector Perform | $39 | $5 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 5, 2026Q2 FY26 | −$1.01 | −$1.09 | −7.9% | $451.2K | $507.0K | +12.4% | +4.97% |
| May 6, 2026Q1 FY26 | −$0.79 | −$0.99 | −25.3% | $352.8K | $696.0K | +97.3% | +0.45% |
| Mar 4, 2026Q4 FY25 | −$0.78 | −$0.81 | −3.8% | $994.5K | $620.0K | −37.7% | −12.44% |
| Nov 5, 2025Q3 FY25 | −$0.77 | −$0.85 | −10.4% | $1.0M | $966.0K | −4.0% | +0.54% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $24.5M | $5.3M | $966.0K | $620.0K | $696.0K | $507.0K | |
| Gross profit | $23.6M | $5.2M | $245.0K | $245.0K | $168.0K | $507.0K | |
| Operating income | −$48.8M | −$62.2M | −$62.0M | −$70.3M | −$87.2M | −$97.4M | |
| Net income | −$45.2M | −$59.4M | −$59.7M | −$67.6M | −$84.8M | −$94.5M | |
| Diluted EPS | −$0.65 | −$0.85 | −$0.85 | −$0.81 | −$0.99 | −$1.09 | |
| Gross margin | 96.7% | 96.9% | 25.4% | 39.5% | 24.1% | 100.0% | |
| Operating margin | -199.7% | -1,166.8% | -6,420.8% | -11,346.0% | -12,532.5% | -19,207.1% |
Fiscal years (4-quarter sums)FY21 $36.9M · FY22 $41.4M · FY23 $46.0M · FY24 $43.3M · FY25 $31.4M
Revenue by product · FY24
Revenue by geography · FY24
Balance sheet, Jun 30, 2026Cash & short-term investments $180.5M · Total debt $22.4M · Total assets $228.2M · Shareholders' equity $166.4M
Dividends
No dividends on record.
Ownership
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 83.84M · Float 70.47M · 84.1% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Suvretta Capital Management, LLC | 8.30M | 9.90% | 13F | Aug 14, 2026 |
| BlackRock, Inc. | 7.46M | 8.90% | 13F | Aug 7, 2026 |
| Cormorant Asset Management, LP | 7.00M | 8.35% | 13F | Aug 14, 2026 |
| Federated Hermes, Inc. | 5.68M | 6.78% | 13F | Aug 12, 2026 |
| Adage Capital Partners GP, L.L.C. | 4.83M | 5.76% | 13F | Aug 14, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 18, 2026 | Karen L. Zaderej | director | +10,600 | $4.93 |
| Jun 30, 2026 | Ramiro Ribeiro | officer: Chief Medical Officer | −4,875 | $15.01 |
| Apr 17, 2026 | Ramiro Ribeiro | officer: Chief Medical Officer | −2,437 | $15.00 |
| Mar 16, 2026 | Jay S. Duker | director, officer: President and CEO | +1,500 | $13.15 |
| Mar 4, 2026 | Ramiro Ribeiro | officer: Chief Medical Officer | −2,438 | $17.87 |
Peers
- Regeneron
Dominant aflibercept incumbent in wet AMD and DME
- Ocular Therapeutix
Phase 3 axitinib implant peer for durable wet AMD therapy
- Novartis (ADR)
Approved anti-VEGF rival through Beovu in wet AMD and DME
- Harrow
U.S. anti-VEGF biosimilar marketer through BYOOVIZ and OPUVIZ
- Alcon
Global eye-care player developing AR-14034 for wet AMD
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| EyePoint | $4.51 | +0.74% | $375.6M | — | — | 134.7 | −90.5% |
| Regeneron | $793.21 | −0.11% | $81.82B | 19.6 | 13.1 | 5.3 | +16.7% |
| Ocular Therapeutix | $10.45 | +0.87% | $2.27B | — | — | 43.6 | +0.1% |
| Novartis (ADR) | $153.81 | 0.00% | $292.35B | 23.2 | 16.4 | 5.3 | +0.9% |
| Harrow | $37.77 | +1.29% | $1.39B | — | 30.3 | 5.0 | +10.9% |
| Alcon | $72.15 | +0.21% | $35.12B | 55.4 | 18.6 | 3.3 | +7.5% |
| Median | 23.2 | 17.5 | 5.3 | +7.5% |